Floatz logo

Teriflunomide

Relapsing Multiple Sclerosis

University Hospital, MontpellierSmall moleculePhase 4 / ApprovedActive
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
69/ 100
Competitive Position
81/ 100

Competitive context

79 Active assets in the Relapsing Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Fingolimod
TG Therapeutics, Inc.
Phase 4A
Natalizumab
Biogen
Phase 4BBB
Glatiramer
University Hospital, Montpellier
Phase 4BBB
Interferon ?1 (human fibroblast protein moiety)
Biogen
Phase 4BBB
Cladribine
Uppsala University
Phase 4BBB

View all 50 →

Same molecule, other indications

Teriflunomide is also rated in:

multiple sclerosisDormant
BBB
Indicative ·
72 / 100
View asset →
secondary progressive multiple sclerosisDormant
B
Indicative ·
60 / 100
View asset →
progressive relapsing multiple sclerosisDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →